文献速递腹部CT

预测接受联合靶向免疫治疗的晚期肝细胞癌患者生存:容积影像参数评估

Predicting survival of patients with advanced hepatocellular carcinoma receiving combination targeted immunotherapy: an evaluation of volumetric imaging parameters.
PubMed 文献 · Abdom Radiol (NY) · 2024-03-28

回顾性分析40例接受靶向免疫治疗的晚期肝细胞癌患者的基线和随访增强腹部CT,计算存活肿瘤体积和肿瘤存活百分比。基线存活百分比>69%且存活百分比降低≥8%的患者总生存期显著更高,多变量分析证实两者为独立预测因素。基于此建立的预后分层系统将患者分为较好、中等和较差预后组,较好预后组总生存期最高。

要点

  • 基线肿瘤存活百分比>69%且治疗后存活百分比降低≥8%提示较好预后。
  • 肿瘤存活百分比及其降低幅度是多变量分析证实的独立总生存预测因素。
  • RECIST评估多数(97.5%)为疾病稳定,但容积参数可进一步区分预后。

核心结论

  • 肿瘤存活百分比和存活百分比降低可预测接受免疫治疗的肝细胞癌患者总生存期。

研究设计与样本

  • 回顾性分析纳入40例接受靶向免疫治疗的晚期肝细胞癌患者,分析基线和随访增强腹部CT,选取最大肿瘤为指标病灶,计算存活肿瘤体积和肿瘤存活百分比。

关键影像表现/征象

  • 基线存活百分比>69%且存活百分比降低≥8%的患者总生存期显著更高。
  • 多变量分析证实存活百分比和存活百分比降低为总生存期的显著预测因素。
  • 预后分层系统将患者分为较好、中等和较差预后组,较好预后组总生存期最高。
  • 按RECIST评估97.5%的患者为疾病稳定,而预后模型重新分类为较好预后47.5%、中等预后37.5%、较差预后15%。

诊断标准与关键数值

  • 较好预后:基线肿瘤存活百分比>69%且存活百分比降低≥8%。
  • 较差预后:基线肿瘤存活百分比≤69%且存活百分比降低<8%。
  • 中等预后:其余患者。

临床应用与阅片要点

  • 容积参数肿瘤存活百分比及其降低幅度可用于预测接受靶向免疫治疗的晚期肝细胞癌患者的总生存期。
  • 基于基线存活百分比>69%和存活百分比降低≥8%的预后分层系统可将患者分为较好、中等和较差预后组。
  • RECIST评估为疾病稳定的患者中,容积参数可进一步区分不同预后亚组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate the potential of volumetric imaging in predicting survival of advanced hepatocellular carcinoma (HCC) patients receiving immunotherapy.

METHODS: Retrospective analysis included 40 patients with advanced HCC who received targeted immunotherapy. Baseline and follow-up contrast-enhanced abdominal computed tomography (CT) scans were analyzed. The largest tumor was chosen as the index lesion. Viable tumor volume (qViable) and percentage tumor viability (%Viability) were calculated. Response Evaluation Criteria in Solid Tumors (RECIST) and Tumor volume change after treatment (qRECIST) were measured. Associations with overall survival (OS) were assessed. Cox regression analysis assessed the association between variables and overall survival (OS). A new prognostic stratification system was attempted to categorize patients based on significant predictors of OS. Patients with a baseline %viability > 69% and %viability reduction ≥ 8% were classified as better prognosis. Patients were stratified into better, intermediate and worse prognosis groups based on baseline %viability > 69% and ≥ 8% %viability reduction (better prognosis); baseline %viability ≤ 69% and < 8% %viability reduction (worse prognosis); remainder were intermediate prognosis.

RESULTS: Patients with baseline %Viability > 69% and %Viability reduction ≥ 8% showed significantly higher OS. Multivariate analysis confirmed %Viability and %Viability reduction as significant predictors of OS. A prognostic stratification system using these parameters stratified patients into better, intermediate and worse prognosis groups, with the better prognosis showing highest OS. Most patients (97.5%) had stable disease by RECIST while the prognostic model re-classified 47.5% as better prognosis, 37.5% intermediate prognosis, and 15% worse prognosis.

CONCLUSION: Volumetric parameters of %Viability and %Viability reduction predict OS in HCC patients undergoing immunotherapy.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Mohseni A, Baghdadi A, Madani SP, et al. Predicting survival of patients with advanced hepatocellular carcinoma receiving combination targeted immunotherapy: an evaluation of volumetric imaging parameters. Abdom Radiol (NY). 2024. PMID: 38546828. doi:10.1007/s00261-024-04257-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。